CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021
Authors:
Dong‐Wan Kim
Sang‐We Kim
D. Ross Camidge
Catherine A. Shu
Kristen A. Marrone
Xiuning Le
Collin M. Blakely
Keunchil Park
Gee‐Chen Chang
Sandip Pravin Patel
Gozde Kar
Zachary A. Cooper
Ramin Samadani
Michael Pluta
Rakesh Kumar
Suresh S. Ramalingam
Affiliated Authors:
Catherine A. Shu
Columbia Affiliation:
Subjects:
Antineoplastic Agents (MeSH)
Carcinoma, Non-Small-Cell Lung (MeSH)
Lung Neoplasms (MeSH)
Cancer Immunotherapy (OpenAlex Topic)
Advancements in Lung Cancer Research (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Author Keywords:
cd73
egfr tki resistance
non–small-cell lung cancer
t790m-negative
elink
Publication Type:
Article
Unique ID:
10.1016/j.jtho.2022.12.021
PMID:
36641093
DOI:
10.1016/j.jtho.2022.12.021
Journal:
Journal of Thoracic Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: